We make no representation about the suitability of any compound covered here for any particular purpose.

Can two short peptides, each with a narrow focus, produce a broader effect when combined? That is the question researchers ask about Thymalin and Cortagen. Both belong to a class of compounds called bioregulator peptides, originally isolated from animal tissues and studied for decades in Russia and Eastern Europe. Thymalin targets the thymus and immune function. Cortagen targets the nervous system. A stack of the two is often discussed in anti-aging circles, but the published evidence for synergy remains limited.

In a 2020 paper published in Peptides, Chang and colleagues reviewed the history of peptide bioregulators and noted that most clinical data come from small, short-term trials conducted before modern regulatory standards. That caveat applies to Thymalin and Cortagen alike. Still, the mechanistic rationale for combining them is worth examining.

Thymalin: A Thymic Peptide with Immunomodulatory Effects

Thymalin is a dipeptide composed of glutamic acid and tryptophan. It was developed in the 1970s by Russian researchers who extracted it from calf thymus. The peptide is thought to influence T-cell maturation and cytokine balance, though the exact receptor interactions are not fully mapped. A 2019 review in Aging and Disease described Thymalin as one of the most studied thymic peptides for immunosenescence, the age-related decline in immune function.

Human trials of Thymalin are mostly from the 1980s and 1990s. A 1994 study in elderly patients reported improvements in some immune parameters after a 10-day course. However, those studies used varying endpoints and lacked placebo controls in many cases. More recent work has focused on animal models. In a 2018 experiment, Thymalin administration in aged rats was associated with changes in T-cell subsets and reduced markers of inflammation. The relevance to human aging is still unclear.

Thymalin is often compared to other thymic peptides like Thymosin Alpha-1, but the two are chemically distinct. Thymalin's small size may allow oral absorption, though most research uses injection. The peptide has also been studied in combination with Epitalon, another bioregulator, for effects on the pineal-thymic axis. A related article on this site explores whether a Thymalin-Epitalon stack can rejuvenate that axis.

Cortagen: A Neuroprotective Peptide with a Different Target

Cortagen is a tetrapeptide (Ala-Glu-Asp-Gly) originally derived from the cerebral cortex. It was designed to support neuronal function and has been studied in models of stroke, traumatic brain injury, and age-related cognitive decline. A 2016 paper in Bulletin of Experimental Biology and Medicine reported that Cortagen improved memory and reduced oxidative stress in aged rats. Human data are sparse, with a few small trials in patients with cerebrovascular disease.

The mechanism of Cortagen is not fully understood. It may modulate gene expression in neurons and glial cells, possibly through interactions with DNA or transcription factors. Unlike Thymalin, Cortagen has no known effect on the thymus. Its neuroprotective profile makes it a candidate for combination with immune-focused peptides, on the theory that neuroinflammation and immunosenescence are linked in aging.

Some researchers have proposed that Cortagen and Thymalin together could address both the immune and neural aspects of aging. This idea appears in a 2021 review by Khavinson and colleagues, who suggested that peptide bioregulators may act synergistically when their targets overlap in the neuroimmune axis. However, the review cited no direct evidence from a combined Thymalin-Cortagen trial.

Head-to-Head Evidence: What Exists for the Stack?

There are no published randomized controlled trials that directly compare Thymalin alone, Cortagen alone, and the combination in humans. The closest data come from a 2015 Russian study in elderly patients with chronic cerebral ischemia. That study used a complex of peptides including Thymalin and Cortagen, but the design did not isolate the contribution of each peptide. The authors reported improvements in cognitive scores and immune markers, but the sample size was small and the follow-up was short.

Animal studies offer a bit more. A 2017 experiment in aged mice found that a Thymalin-Cortagen combination reduced markers of brain inflammation and improved T-cell function more than either peptide alone. The effect size was modest, and the study used intraperitoneal injection. Whether the same synergy occurs in humans is unknown.

One reason for the lack of head-to-head data is regulatory. Thymalin and Cortagen are not approved as drugs in the US or EU. They are sold as research chemicals or dietary supplements in some countries, but clinical development has stalled. The FDA's recent peptide panel vote, which proposed a new framework for certain peptides, has renewed interest in compounds like Thymalin. A separate article on this site examines whether Thymalin can clear that new framework.

Where Each Peptide Is Studied More

Thymalin has a longer research history in immunology. Most studies come from Russia and former Soviet states. The peptide is sometimes used in combination with other bioregulators like Epitalon or Vesugen. Cortagen is less studied overall, but its neuroprotective angle has attracted attention in the context of cognitive aging. Neither peptide has a strong safety database by modern standards.

For researchers interested in mitochondrial peptides, MOTS-c has a different profile. MOTS-c is a mitochondrial-derived peptide that may influence metabolic health and exercise capacity. It is not a bioregulator in the same sense as Thymalin, but some longevity protocols combine MOTS-c with NAD+ precursors. This site has covered how MOTS-c and NAD+ synergize in mitochondrial protocols. The comparison is useful because MOTS-c has more recent human data than Thymalin or Cortagen.

Epitalon, another Russian peptide, is often stacked with Thymalin for pineal-thymic effects. A 2019 trial in elderly patients reported that a Thymalin-Epitalon combination reduced mortality over a 12-year follow-up. That study, while intriguing, had methodological limitations. Cortagen is not typically included in such stacks, which raises the question of whether adding it would change outcomes.

The bottom line for researchers: Thymalin and Cortagen have plausible but unproven synergy. The immune and neural systems do interact in aging, and peptides that target each system could theoretically complement one another. But the evidence is mostly from animal models and small, uncontrolled human studies. Anyone considering this stack for research purposes should review the primary literature carefully.

Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.